120450-05-7 Usage
Uses
Used in Pharmaceutical Industry:
2-AMino-4-(p-tolyl)-1H-pyrrole-3-carbonitrile is used as an intermediate in the preparation of azaheteroarylacrylamide derivatives. These derivatives are known to possess kinase inhibitory properties, which are crucial in the development of drugs targeting various diseases, including cancer and other proliferative disorders. The compound's role in the synthesis of these inhibitors highlights its importance in the pharmaceutical industry for the development of novel therapeutic agents.
Used in Chemical Synthesis:
Beyond its pharmaceutical applications, 2-AMino-4-(p-tolyl)-1H-pyrrole-3-carbonitrile may also find use in other areas of chemical synthesis. Its unique structural features make it a potentially valuable building block for the creation of various organic compounds with different applications, such as materials science, agrochemicals, or other specialty chemicals. The versatility of 2-AMino-4-(p-tolyl)-1H-pyrrole-3-carbonitrile in synthesis could lead to the discovery of new compounds with diverse applications.
Check Digit Verification of cas no
The CAS Registry Mumber 120450-05-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,0,4,5 and 0 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 120450-05:
(8*1)+(7*2)+(6*0)+(5*4)+(4*5)+(3*0)+(2*0)+(1*5)=67
67 % 10 = 7
So 120450-05-7 is a valid CAS Registry Number.
120450-05-7Relevant academic research and scientific papers
KINASE INHIBITORS
-
Paragraph 0280; 0281, (2013/03/26)
Methods of inhibiting kinases using kinase inhibitors having olefin moieties are disclosed.
SELECTIVE SERINE/THREONINE KINASE INHIBITORS
-
Page/Page column 28, (2008/06/13)
Inhibition of protein kinases having one or more cysteine residues within the ATP binding site is effected by contacting the kinase, per se or in a cell or subject, with an inhibitory-effective amount of a compound having a heterocyclic core structure comprised of two or more fused rings containing at least one nitrogen ring atom, and an electrophilic substituent that is capable of reacting with a cysteine residue within the ATP binding site of a kinase. Preferred compounds include certain pyrrolopyrimidines and oxindoles having such an electrophilic substituent and optionally an aromatic or heteroaromatic substituent that is capable of interacting with a threonine or smaller residue located in the gatekeeper position of the kinase. Kinases lacking such cysteine residues may be engineered or modified so that they are capable of being inhibited by such compounds by replacing a valine or other amino acid residue within the ATP binding site by a cysteine residue.
